Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.87
-0.2400-1.83%
Pre-market: 12.75-0.1200-0.93%07:48 EDT
Volume:3.44M
Turnover:44.60M
Market Cap:1.80B
PE:-3.85
High:13.49
Open:13.11
Low:12.68
Close:13.11
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.09
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.48
PE(LYR):-3.38

Loading ...

Intellia to report Phase 3 HAELO trial topline data for lonvo-z on April 27

Reuters
·
Apr 25

Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws

TIPRANKS
·
Apr 11

Intellia bylaws set US federal courts as exclusive forum for Securities Act claims

Reuters
·
Apr 11

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade

Simply Wall St.
·
Apr 07

Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan

Reuters
·
Apr 04

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 04

Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

Simply Wall St.
·
Mar 10

Intellia Therapeutics Awards 16,500 RSU Inducement Grants Under 2024 Plan

Reuters
·
Mar 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Intellia Therapeutics Raised to Buy From Hold by Jones Trading

Dow Jones
·
Mar 04

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 04

Stock Track | Intellia Therapeutics Soars 5.77% in Pre-Market After Analyst Upgrade to Buy

Stock Track
·
Mar 04

Intellia Therapeutics Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS
·
Mar 04

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

Stock Track | Intellia Therapeutics Plummets 7.34% Intraday on Dilution Fears from $400 Million Stock Sale Plan

Stock Track
·
Mar 03

Intellia Presents Three-Year Lonvo-z Data Showing 96% HAE Attack Reduction

Reuters
·
Mar 03

RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 03

Intellia Therapeutics price target lowered to $48 from $54 at Canaccord

TIPRANKS
·
Mar 03

Intellia Therapeutics, Inc. : Wells Fargo Raises Target Price to $15 From $12

THOMSON REUTERS
·
Mar 03

Stock Track | Intellia Therapeutics Plunges 6.02% in Pre-market on $400 Million Stock Sale Plan

Stock Track
·
Mar 03